GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute

LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.

Sabin Vaccine Institute and The Aspen Institute Release Report Calling for Bold, New, and Coordinated Commitments to Making Universal Influenza Vaccines a Reality

WASHINGTON, D.C. – A new report released today by the Sabin-Aspen Vaccine Science & Policy Group, a joint initiative of the Sabin Vaccine Institute and the Aspen Institute, calls for an urgent, coordinated effort to amplify and focus resources on the long-sought, but overdue achievement of a universal influenza vaccine (UIV).

Dr. Carol Baker Receives 2019 Albert B. Sabin Gold Medal

Washington, D.C. – The Sabin Vaccine Institute (Sabin) today announced it will present its annual Albert B. Sabin Gold Medal to Dr. Carol J. Baker, whose groundbreaking research in Group B Streptococcus (GBS) is accelerating progress toward a much-needed vaccine to prevent a bacterial infection that can cause lifelong illness or death in newborns.

Multidisciplinary Experts Leverage Global Action for Local Impact to Protect Communities at Risk of Typhoid and Related Diseases

HANOI, VIETNAM – Beginning today, the 11th International Conference on Typhoid and Other Invasive Salmonelloses brings together more than 450 researchers, policy makers and advocates who are dedicated to improving the lives of young children and their families suffering from typhoid, paratyphoid and invasive non-typhoidal Salmonella.

Pages